Back to Home
    Fundamentals

    What Is Angiogenesis, and Why Does It Matter for Stem Cell Therapy?

    By RegenMed Review Editorial Team · Medically Reviewed by the RegenMed Review Editorial Team
    November 11, 20267 min read
    What Is Angiogenesis, and Why Does It Matter for Stem Cell Therapy?

    What this article covers

    What This Article Covers
    Angiogenesis — the formation of new blood vessels from existing ones — is one of the body's most fundamental repair tools, and it's also one of the main reasons stem cells, particularly mesenchymal stem cells (MSCs), are being studied for conditions involving poor blood flow. This article explains what angiogenesis is, why the body relies on it for everything from healing a cut to recovering from a heart attack, how MSCs are thought to encourage new vessel growth through the signals they release, and why this mechanism is generating real interest — and real caution — for conditions like critical limb ischemia, chronic wounds, and cardiac repair.
    What Is Angiogenesis, Exactly?
    Angiogenesis is the process by which new blood vessels sprout from existing ones. According to the National Cancer Institute, it is simply "the formation of new blood vessels," driven by the movement, growth, and specialization of the cells that line vessel walls (endothelial cells).
    Why the Body Depends on It for Healing
    Any tissue that's cut, burned, or starved of blood flow faces the same basic problem: repair requires oxygen, nutrients, and immune cells, and all of those arrive by blood vessel. Without new vessels growing into the damaged area, healing stalls.
    How Stem Cells Are Thought to Promote New Vessel Growth
    Mesenchymal stem cells are one of the most studied cell types for therapeutic angiogenesis, and the mechanism researchers point to is largely paracrine — meaning the cells work mainly by releasing signaling molecules. ) lays out what that secreted "toolkit" looks like: MSCs release a mix of growth factors — including VEGF, basic FGF, TGF-β, PDGF, HGF, and others — along with extracellular vesicles that carry additional VEGF, microRNAs, and other angiogenic cargo.
    Why This Matters for Specific Conditions
    Critical Limb Ischemia. CLI is a severe form of peripheral artery disease where blood flow to the leg is so reduced that tissue is at risk of dying, sometimes leading to amputation.

    What This Article Covers

    Angiogenesis — the formation of new blood vessels from existing ones — is one of the body's most fundamental repair tools, and it's also one of the main reasons stem cells, particularly mesenchymal stem cells (MSCs), are being studied for conditions involving poor blood flow. This article explains what angiogenesis is, why the body relies on it for everything from healing a cut to recovering from a heart attack, how MSCs are thought to encourage new vessel growth through the signals they release, and why this mechanism is generating real interest — and real caution — for conditions like critical limb ischemia, chronic wounds, and cardiac repair.

    What Is Angiogenesis, Exactly?

    Angiogenesis is the process by which new blood vessels sprout from existing ones. According to the National Cancer Institute, it is simply "the formation of new blood vessels," driven by the movement, growth, and specialization of the cells that line vessel walls (endothelial cells). It's distinct from the way the body's original vascular network forms before birth; angiogenesis is the ongoing, adult version — the body's way of extending its plumbing to tissue that needs more blood supply than it's currently getting. This happens constantly in healthy physiology: it's how the lining of the uterus rebuilds each month, how muscle adapts to exercise, and — critically for this article — how injured tissue gets the oxygen and nutrients it needs to rebuild itself.

    Why the Body Depends on It for Healing

    Any tissue that's cut, burned, or starved of blood flow faces the same basic problem: repair requires oxygen, nutrients, and immune cells, and all of those arrive by blood vessel. Without new vessels growing into the damaged area, healing stalls. That's why angiogenesis is a core phase of normal wound healing, alongside inflammation and tissue remodeling. It's also central to recovery after a heart attack, where tissue downstream of a blocked artery is starved of blood, and to conditions like critical limb ischemia (CLI), where arteries in the leg are too narrowed or blocked to keep foot and leg tissue alive. The double-edged part: the same process a healing wound needs is also what a tumor needs. The National Cancer Institute notes that tumors can release chemical signals that trigger angiogenesis, building a blood supply that lets them grow and spread — which is why an entire class of cancer drugs (angiogenesis inhibitors) works by blocking this process. Angiogenesis itself is neither "good" nor "bad"; it's a biological tool that depends entirely on context.

    How Stem Cells Are Thought to Promote New Vessel Growth

    Mesenchymal stem cells are one of the most studied cell types for therapeutic angiogenesis, and the mechanism researchers point to is largely paracrine — meaning the cells work mainly by releasing signaling molecules. A 2020 review in Stem Cells International (Maacha et al.) lays out what that secreted "toolkit" looks like: MSCs release a mix of growth factors — including VEGF, basic FGF, TGF-β, PDGF, HGF, and others — along with extracellular vesicles that carry additional VEGF, microRNAs, and other angiogenic cargo. In laboratory experiments, neutralizing VEGF (along with MCP-1 and IL-6) significantly blunted the angiogenic activity of MSC-conditioned fluid — clear evidence that VEGF signaling is doing real work here. The review also notes that MSCs under mild stress, such as low oxygen, tend to ramp up production of these angiogenic factors, one reason researchers are interested in "priming" cells before use. A related 2020 study in Stem Cells Translational Medicine (Zhu et al.) found that umbilical cord MSCs pretreated with inflammatory signals produced more of a growth factor called VEGFC, measurably speeding wound closure and increasing new vessel formation in mice — and when researchers blocked VEGFC, the benefit disappeared entirely. It's worth being direct about the limits here: that's a mouse study, not a human trial, and pretreated-cell approaches are still experimental.

    Why This Matters for Specific Conditions

    Critical Limb Ischemia. CLI is a severe form of peripheral artery disease where blood flow to the leg is so reduced that tissue is at risk of dying, sometimes leading to amputation. Because therapeutic angiogenesis is the whole theoretical appeal of cell therapy here, CLI has become one of the most actively tested applications — and the results so far are mixed and instructive. The PACE trial, a phase III study published in the British Journal of Surgery (2024), tested PLX-PAD (placenta-derived MSC-like cells) in 213 patients unsuitable for revascularization and did not meet its primary endpoint of amputation-free survival (28.6% of treated patients experienced major amputation or death, versus 33% on placebo — not a statistically significant difference). A post hoc subgroup with better blood sugar control showed a signal of benefit at 12 months, but it didn't hold up at 36 months and needs confirmation. Other trials, like the ongoing NOMA trial (a Spanish phase II study using adipose-derived MSCs, described in Trials, 2021), are still working through dosing and safety before efficacy can even be properly assessed. The honest summary: the biology is compelling, but clinical proof that stem cell-driven angiogenesis reliably saves limbs is not yet established.

    Cardiac Repair. After a heart attack, the same VEGF-driven logic applies to heart muscle. Animal research — such as a 2011 study in Cardiovascular Research (Tang et al.) — found that MSCs engineered to produce extra VEGF increased new blood vessel formation in infarcted rat hearts, recruited additional repair-oriented stem cells, reduced the size of the damaged area, and improved heart function. This remains a well-studied mechanism in animal models, underscoring that much of the most mechanistically detailed angiogenesis research is still preclinical rather than tested at scale in people.

    Chronic Wounds. For slow-healing wounds, especially in diabetic patients where poor circulation is often part of the problem, the same VEGF/paracrine pathway is the proposed reason MSC-based approaches are being explored — rebuilding local blood supply to a wound bed that isn't healing on its own.

    Bottom Line

    Angiogenesis is a normal, essential biological process — the body's way of growing new blood supply to tissue that needs it, whether that's a healing wound, a recovering heart, or, less helpfully, a tumor. Mesenchymal stem cells appear to encourage this process mainly through the growth factors and signaling molecules they release, with VEGF consistently showing up as a key player across wound healing, limb ischemia, and cardiac research. But "promotes angiogenesis in a dish or a mouse" is a long way from "proven therapy," and the largest human trial in this space to date (PACE, for critical limb ischemia) missed its main goal. Angiogenesis is a mechanism, not a treatment in itself — and like most regenerative medicine concepts, it deserves genuine scientific enthusiasm paired with a clear eye on how much is still unproven in people.

    Key Questions Answered

    What is angiogenesis?
    It is the formation of new blood vessels from existing ones, driven by the cells that line vessel walls. The body uses it for healing, exercise adaptation and tissue repair.
    How are MSCs thought to promote new blood vessels?
    Mainly through paracrine signaling: they release growth factors such as VEGF, FGF, PDGF and HGF, plus extracellular vesicles carrying angiogenic cargo.
    Has stem cell-driven angiogenesis been proven to save limbs?
    No. The phase III PACE trial in critical limb ischemia did not meet its primary endpoint of amputation-free survival, and other trials are still at earlier stages.

    Sources

    • "Angiogenesis Inhibitors," National Cancer Institute (cancer.gov), 2018, https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/angiogenesis-inhibitors-fact-sheet
    • Maacha S, Sidahmed H, Jacob S, et al., "Paracrine Mechanisms of Mesenchymal Stromal Cells in Angiogenesis," Stem Cells International, 2020, https://pmc.ncbi.nlm.nih.gov/articles/PMC7085399
    • Zhu M, Chu Y, Shang Q, et al., "Mesenchymal Stromal Cells Pretreated with Pro-Inflammatory Cytokines Promote Skin Wound Healing Through VEGFC-Mediated Angiogenesis," Stem Cells Translational Medicine, 2020, https://pmc.ncbi.nlm.nih.gov/articles/PMC7519767
    • "PACE: Randomized Controlled Multicentre Multinational Phase III Study of PLX-PAD for Critical Limb Ischaemia in Patients Unsuitable for Revascularization," British Journal of Surgery, 2024, https://pluri-biotech.com/wp-content/uploads/2024/02/znad437.pdf
    • "Efficacy and Safety of Intramuscular Administration of Allogeneic Adipose Tissue Derived and Expanded Mesenchymal Stromal Cells in Diabetic Patients with Critical Limb Ischemia (The NOMA Trial)," Trials, 2021, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420067/
    • Tang JM, Wang JN, Zhang L, et al., "VEGF/SDF-1 Promotes Cardiac Stem Cell Mobilization and Myocardial Repair in the Infarcted Heart," Cardiovascular Research, 2011, https://pmc.ncbi.nlm.nih.gov/articles/PMC3139446

    Related Articles

    The Review Dispatch

    Our weekly briefing on the regenerative medicine landscape, for researchers, clinicians, and investors.

    regenmedreview

    regenmedreview is an independent reference library covering stem cell therapy and cancer immunotherapy research — compiled for researchers, clinicians, and patients exploring the field.

    The information on this site is for general educational purposes only and does not constitute medical advice. Regenerative medicine treatments discussed here may not be approved or available in all jurisdictions. Always consult a licensed physician before making treatment decisions.

    © 2026 regenmedreview. All rights reserved.Independent. Unaffiliated. Reader-supported.